
-
ESSA Pharma NASDAQ:EPIX ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer.
Location: | Website: www.essapharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-43.9M
Cash
120.6M
Avg Qtr Burn
-5.60M
Short % of Float
2.41%
Insider Ownership
6.02%
Institutional Own.
71.00%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Masofaniten (EPI-7386) (antiandrogen) Monotherapy Details Castration-resistant prostate cancer | Failed Discontinued | |
Masofaniten (EPI-7386) (antiandrogen) + apalutamide and abiraterone acetate Details Cancer, Prostate cancer | Failed Discontinued | |
Masofaniten (EPI-7386) (antiandrogen) combo w/ enzalutamide Details Prostate cancer, Cancer | Failed Discontinued |